CytoMed Therapeutics (CytoMed Therapeutics) Float Percentage Of Total Shares Outstanding : 14.78% (As of May. 29, 2024)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CytoMed Therapeutics's float shares is 1.71 Mil. CytoMed Therapeutics's total shares outstanding is 11.54 Mil. CytoMed Therapeutics's float percentage of total shares outstanding is 14.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CytoMed Therapeutics's Insider Ownership is 5.91%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CytoMed Therapeutics's Institutional Ownership is 0.04%.

CytoMed Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CytoMed Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.71	/	11.54
	=	14.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

F98:Germany

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

Executives

Chee Kong Choo	director, 10 percent owner	COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng	director, officer: CSO and CMO	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang	10 percent owner	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan	director, officer: Chief Operating Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd	10 percent owner	18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee	director, officer: Chief Clinical Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh	director	1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544